Perspective Therapeutics (NYSE:CATX) Raised to Strong-Buy at Cantor Fitzgerald

Perspective Therapeutics (NYSE:CATX) was upgraded by research analysts at Cantor Fitzgerald to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

Other research analysts have also issued reports about the stock. Oppenheimer cut their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Royal Bank of Canada reissued an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $24.00 to $5.00 in a research report on Monday, November 25th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Friday, January 24th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Perspective Therapeutics has an average rating of “Buy” and an average price target of $15.14.

Perspective Therapeutics Price Performance

Shares of CATX opened at $2.35 on Tuesday. Perspective Therapeutics has a 52-week low of $2.32 and a 52-week high of $19.05. The business’s 50 day moving average price is $3.24 and its two-hundred day moving average price is $7.91.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its position in shares of Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after buying an additional 5,370,392 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after acquiring an additional 355,685 shares during the last quarter. Deerfield Management Company L.P. Series C increased its position in shares of Perspective Therapeutics by 4.3% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock valued at $9,375,000 after acquiring an additional 120,991 shares during the last quarter. Octagon Capital Advisors LP lifted its holdings in Perspective Therapeutics by 62.1% during the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after acquiring an additional 882,528 shares during the period. Finally, State Street Corp boosted its position in Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.